Journal article
Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II
Antibiotics, Vol.7(2), 35
2018
Abstract
This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.
Details
- Title
- Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II
- Authors
- Wilbert Sybesma (Author) - University of Zurich, SwitzerlandChristine Rohde (Author) - Leibniz Institute, GermanyPavol Bardy (Author) - Masaryk University, Czech RepublicJean-Paul Pirnay (Author) - Queen Astrid Military Hospital, BelgiumIan Cooper (Author) - University of Brighton, United KingdomJonathan Caplin (Author) - University of Brighton, United KingdomNina Chanishvili (Author) - Eliava Institute of Bacteriophage, Microbiology and Virology, GeorgiaAidan Coffey (Author) - Cork Institute of Technology, IrelandDaniel De Vos (Author) - Queen Astrid Military Hospital, BelgiumAmber Hartman Scholz (Author) - Leibniz Institute, GermanyShawna McCallin (Author) - University of Lausanne, SwitzerlandHilke Püschner (Author) - Leibniz Institute, GermanyRoman Pantucek (Author) - Masaryk University, Czech RepublicRustam Aminov (Author) - University of Aberdeen, United KingdomJiří Doškař (Author) - Masaryk University, Czech RepublicD Ipek Kurtboke (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
- Publication details
- Antibiotics, Vol.7(2), 35; 23
- Publisher
- MDPI AG
- Date published
- 2018
- DOI
- 10.3390/antibiotics7020035
- ISSN
- 2079-6382
- Copyright note
- Copyright © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- Organisation Unit
- School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99451463602621
- Output Type
- Journal article
Metrics
14 File views/ downloads
374 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Infectious Diseases
- Pharmacology & Pharmacy